A Morgan Stanley survey of approximately 300 GLP-1 users in February 2024 found 50% were members of a gym, with 70% of those members having joined within the previous 12 months, the same window in which most started taking the drug
Its negative effects can include: Severe gastrointestinal symptoms Risk of thyroid C-cell tumors Pancreatitis Hypoglycemia Rybelsus (semaglutide) Rybelsus, another form of semaglutide, carries similar risks to Ozempic and Wegovy: Gastrointestinal discomfort Risk of thyroid tumors Pancreatic issues Low blood sugar levels Saxenda (liraglutide) Saxenda has been linked to: Thyroid tumors Pancreatitis Gallbladder problems Gastrointestinal issues Mounjaro (tirzepatide) Mounjaro is a newer weight loss drug with side effects that are still being studied
Semaglutide can reduce food intake by about 35-40% compared to a placebo
He enjoys sports, music and traveling with his wife, Elisabeth, and two grown daughters
Novo Nordisk sells the weight loss drug under three different brands: Ozempic injection and Rybelsus tablets for type 2 diabetes, and Wegovy injection for chronic weight management
